Abstract
In 26 AIDS patients treated for toxoplasmic encephalitis, the inhibitory effect on Toxoxplasma growth of sequential sera taken before and after initiation of therapy was determined using a culture-based immunoassay and compared with pyrimethamine blood levels. A marked inhibition of Toxoplasma growth was observed 1 day after initiation of therapy with pyrimethamine plus sulfadiazine and was maintained between 67% and 93% throughout the 15-day follow-up period. The degree of inhibition was not correlated to pyrimethamine blood levels and seemed highly potentiated when sulfadiazine rather than macrolides was given in combination with pyrimethamine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / blood
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Infective Agents / blood
-
Anti-Infective Agents / pharmacology
-
Anti-Infective Agents / therapeutic use*
-
Drug Therapy, Combination
-
Encephalitis / drug therapy*
-
Encephalitis / parasitology
-
Female
-
Follow-Up Studies
-
Humans
-
Macrolides
-
Male
-
Pyrimethamine / blood
-
Pyrimethamine / pharmacology
-
Pyrimethamine / therapeutic use*
-
Sulfadiazine / pharmacology
-
Sulfadiazine / therapeutic use*
-
Toxoplasma / drug effects*
-
Toxoplasma / growth & development
-
Toxoplasmosis, Cerebral / drug therapy*
-
Toxoplasmosis, Cerebral / parasitology
Substances
-
Anti-Bacterial Agents
-
Anti-Infective Agents
-
Macrolides
-
Sulfadiazine
-
Pyrimethamine